Literature DB >> 1362540

Emergence during unsuccessful chemotherapy of multiple drug resistance in a strain of Mycobacterium tuberculosis.

N Rastogi1, B C Ross, B Dwyer, K S Goh, S Clavel-Sérès, V Jeantils, P Cruaud.   

Abstract

Serial isolates of Mycobacterium tuberculosis were cultured from a patient who failed to respond to standard antituberculous chemotherapy. Isolates were cultured in March 1989, July 1989, December 1989 and May 1990. Each successive isolate was found to be resistant to a wider range of antituberculous drugs than its predecessors. The initial isolate was resistant to isoniazid and rifampin, the second isolate was also resistant to ethambutol, the third was also resistant to pyrazinamide, ansamycin (= rifabutin) and ofloxacin and the last isolate was also resistant to ciprofloxacin and sparfloxacin. All four isolates' bacteriophage typing profiles and DNA restriction fragment patterns determined by Southern blot hybridization using the IS6110/IS986 probes and the new probe pTBN12 were concordant. It was concluded that this patient was persistently infected with a single strain of Mycobacterium tuberculosis which developed resistance to a number of families of drugs but did not show any significant change in typing patterns. The problem of acquired multiple drug resistance, particularly to fluoroquinolones and rifamycins, represents a new challenge in tuberculosis therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1362540     DOI: 10.1007/bf01962370

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  20 in total

1.  Emergence of drug-resistant Mycobacterium tuberculosis in HIV-infected patients.

Authors:  L Monno; G Angarano; S Carbonara; S Coppola; D Costa; M Quarto; G Pastore
Journal:  Lancet       Date:  1991-04-06       Impact factor: 79.321

2.  The U-shaped curve of concern.

Authors:  L B Reichman
Journal:  Am Rev Respir Dis       Date:  1991-10

3.  Polymerase chain reaction amplification of a repetitive DNA sequence specific for Mycobacterium tuberculosis.

Authors:  K D Eisenach; M D Cave; J H Bates; J T Crawford
Journal:  J Infect Dis       Date:  1990-05       Impact factor: 5.226

4.  Chromosomal DNA fingerprint patterns produced with IS6110 as strain-specific markers for epidemiologic study of tuberculosis.

Authors:  G H Mazurek; M D Cave; K D Eisenach; R J Wallace; J H Bates; J T Crawford
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

5.  Activity of five fluoroquinolones against Mycobacterium avium-intracellulare complex and M. xenopi.

Authors:  N Rastogi; K S Goh; H L David
Journal:  Ann Inst Pasteur Microbiol       Date:  1988 Mar-Apr

6.  Differentiation of Mycobacterium tuberculosis strains by use of a nonradioactive Southern blot hybridization method.

Authors:  B C Ross; K Raios; K Jackson; A Sievers; B Dwyer
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

7.  In vitro activity of the new difluorinated quinolone sparfloxacin (AT-4140) against Mycobacterium tuberculosis compared with activities of ofloxacin and ciprofloxacin.

Authors:  N Rastogi; K S Goh
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

8.  [Distribution of bacteriophage types of Mycobacterium tuberculosis in France].

Authors:  S Clavel-Sérès; F Clément; C Jimenez-Misas
Journal:  Rev Mal Respir       Date:  1988       Impact factor: 0.622

9.  Resurgent tuberculosis in New York City. Human immunodeficiency virus, homelessness, and the decline of tuberculosis control programs.

Authors:  K Brudney; J Dobkin
Journal:  Am Rev Respir Dis       Date:  1991-10

10.  Insertion element IS986 from Mycobacterium tuberculosis: a useful tool for diagnosis and epidemiology of tuberculosis.

Authors:  P W Hermans; D van Soolingen; J W Dale; A R Schuitema; R A McAdam; D Catty; J D van Embden
Journal:  J Clin Microbiol       Date:  1990-09       Impact factor: 5.948

View more
  15 in total

Review 1.  Future directions in the development of new antitubercular drugs. Where do we go from here?

Authors:  W W Yew; C H Chau
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

2.  Usefulness of the secondary probe pTBN12 in DNA fingerprinting of Mycobacterium tuberculosis.

Authors:  F Chaves; Z Yang; H el Hajj; M Alonso; W J Burman; K D Eisenach; F Dronda; J H Bates; M D Cave
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

Review 3.  Systematic review of clofazimine for the treatment of drug-resistant tuberculosis.

Authors:  M Gopal; N Padayatchi; J Z Metcalfe; M R O'Donnell
Journal:  Int J Tuberc Lung Dis       Date:  2013-03-25       Impact factor: 2.373

Review 4.  The role of fluoroquinolones in tuberculosis today.

Authors:  S E Berning
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  Detection of a previously unamplified spacer within the DR locus of Mycobacterium tuberculosis: epidemiological implications.

Authors:  I Filliol; C Sola; N Rastogi
Journal:  J Clin Microbiol       Date:  2000-03       Impact factor: 5.948

6.  Mycobacterium tuberculosis transmission between cluster members with similar fingerprint patterns.

Authors:  Kashef Ijaz; Zhenhua Yang; H Stewart Matthews; Joseph H Bates; M Donald Cave
Journal:  Emerg Infect Dis       Date:  2002-11       Impact factor: 6.883

7.  Comparison of various repetitive DNA elements as genetic markers for strain differentiation and epidemiology of Mycobacterium tuberculosis.

Authors:  D van Soolingen; P E de Haas; P W Hermans; P M Groenen; J D van Embden
Journal:  J Clin Microbiol       Date:  1993-08       Impact factor: 5.948

8.  Reduced NK activity correlates with active disease in HIV- patients with multidrug-resistant pulmonary tuberculosis.

Authors:  L T Ratcliffe; P T Lukey; C R MacKenzie; S R Ress
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

9.  Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex.

Authors:  N Rastogi; K S Goh; A Bryskier
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

Review 10.  Clinical pharmacokinetics of rifabutin.

Authors:  M H Skinner; T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.